Dupilumab therapy in children aged 2-12？years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study.

Pre One:Effectiveness and safety of dupilumab in moderate-to-severe atopic dermatitis patients with chronic renal insufficiency: a real-world retrospective study in China.

Next One:Plasma adenosine is linked to disease activity and response to treatment in patients with chronic spontaneous urticaria